Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within  days prior to randomization. The minimum sensitivity of the pregnancy test must be  IU/L or equivalent units of HCG.
Women of childbearing potential (WOCBP) only: Negative urine or serum pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG])\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of nivolumab
Women of childbearing potential (WOCPB) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours of starting study therapy
Women of child bearing potential who are pregnant as evidenced by positive serum pregnancy test (minimum sensitivity  IU/L or equivalent units of HCG) or nursing.
WOCBP must have a negative serum or urine pregnancy test result (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  to  hours before the first dose of study drug
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  iu/l or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of nivolumab
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropic [HCG]) within  hours prior to the start of the study drug
PHASE II INCLUSION CRITERIA: Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropic [HCG]) within  hours prior to the start of the study drug
Patient must be non-pregnant and non-nursing; women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to randomization
Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours of the start of study drugs
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of nivolumab; elevated HCG for other explained and documented reasons is allowed
Ability to become pregnant (or already pregnant or lactating); women and men who want to participate have to agree to use two highly effective forms of contraceptive prior to study entry, for the duration of study participation, and for  days following completion of therapy, to be eligible; women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of study drug
Women of childbearing potential (WOCBP) must have a negative serum test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of investigational product
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of nivolumab
Women of childbearing potential must have a negative serum pregnancy test (minimum sensitivity of  IU/L or equivalent units of human chorionic gonadotropin [HCG]) performed within  hours prior to the start of nivolumab; post-menopausal women (defined as no menses for at least  year) and surgically sterilized women are not required to undergo a pregnancy test
Pregnant or breast-feeding patients; women of childbearing potential must have a pregnancy test (minimum sensitivity of  IU/L or equivalent units of HCG) performed within  hours prior to the start of nivolumab, and a negative result must be documented before start of treatment
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [hCG] hormone) within  hours prior to the start of study drug
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [hCG]) within  days prior to the start of study drug
Participants who are women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin) within  hours prior to the start of study drug
Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  days of the study enrollment
Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  days of study enrollment
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of investigational product.
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of the study drug.
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) during screening and within  hours prior to the first dose of nivolumab
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of investigational product.
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of study drug
Pregnancy or lactating females; women of childbearing potential must have a negative serum pregnancy test (minimum sensitivity  IU/L or equivalent units of HCG) within  hours prior to Step  registration
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (sensitivity =< IU HCG/L) within  weeks prior to registration and will be repeated within  hours prior to the start of study drug administration
WOCBP must have a negative serum test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of investigational product
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of nivolumab
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG])
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of study drug
Pregnant or breastfeeding; for elotuzumab arm: women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  days of study treatment start ( hours prior to the start of elotuzumab)
Female patients of childbearing potential (not postmenopausal for at least  months and not surgically sterile) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  days before study entry; pregnancy test must be repeated if performed >  days before starting study drug
Women must have a negative serum pregnancy test (minimum sensitivity  IU/L or equivalent units of HCG) within  hours prior to the start of investigational product
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of study drug
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of nivolumab; for WOCBP, follow up pregnancy tests will be performed every  weeks (+/- week) during the study regardless of dosing schedules
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of HCG); the first should be performed within  to  days and the second within  hours prior to the start of the study drug; a prescription for lenalidomide for a female of childbearing potential must not be issued by the prescriber until negative pregnancy tests have been verified by the prescriber
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to receiving nivolumab; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of nivolumab
WOCBP must have a negative serum test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of investigational product
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  days prior to the start of study drug
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of study drug
Women of childbearing potential must have a negative serum or urine pregnancy test (sensitivity <  IU human chorionic gonadotropin (HCG)/L) within  hours prior to the start of study drug
Women Of Child Bearing Potential (WOCBP) must have a negative serum or urine pregnancy test (i.e., minimum sensitivity  IU/L or equivalent units of HCG), within  hours prior to the start of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in the study, she should inform her treating physician(s) immediately. **Refer to pg.  of the protocol for the formal definition of a WOCBP.**
Women who are breastfeeding or who are pregnant as evidenced by a positive serum pregnancy test (minimum sensitivity  IU/L or equivalent units of HCG) performed within  days of the first dose of study drug and by a urine pregnancy test (minimum sensitivity  IU/L or equivalent units of HCG) within  hours of the first dose of study drug(s).
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours before the start of ipilimumab
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of thoracic radiation therapy
Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  days of study enrollment
Women of childbearing potential (WOCBP) must have a negative pregnancy test (minimum sensitivity  IU/L or equivalent of human chorionic gonadotropin [HCG]) before entry onto the trial
Participant is neither pregnant nor nursing:\r\n* Women of childbearing potential (WOCBP) must have a negative pregnancy test (minimum sensitivity  IU/L or equivalent of HCG) within  days prior to start of study medication; it is the investigators responsibility to repeat the pregnancy test should start of treatment be delayed
Women of childbearing potential (WOCBP) must have a negative pregnancy test (minimum sensitivity  IU/L or equivalent of human chorionic gonadotropin [HCG]) before entry onto the trial and within  days prior to start of study medication; it is the investigators responsibility to repeat the pregnancy test should start of treatment be delayed
Females of childbearing potential must: use appropriate method(s) of contraception; women of childbearing potential (WOCBP) should use an adequate method to avoid pregnancy for  weeks ( days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of nivolumab
A woman of childbearing potential must have a negative highly sensitive serum [beta-human chorionic gonadotropin (?-hCG)] or urine pregnancy test at (minimum sensitivity  International units (IU)/ liter (L) or equivalent units of HCG) within  days prior to the first dose of study drug
Women must have a negative serum pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of investigational product
Women who are breastfeeding or who are pregnant as evidenced by a positive serum pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin) performed within  days of the first dose of study drug and by a urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours of the first dose of study drug(s)
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  days prior to the start of nivolumab.
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of study treatments
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to the start of investigational product
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  days before the start of ipilimumab
Positive pregnancy screening test with a minimum sensitivity of  IU/L of human chorionic gonadotropin (hCG) within  hours of registration; breastfeeding women are also excluded
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotrophin [HCG]) within  hours before the start of ipilimumab
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) with  days prior to randomization
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [hCG]) within  hours prior to the start of nivolumab
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of HCG) during screening for eligibility assessments and enrollment and within  hours prior to the start of study drug.
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin hormone) within  hours prior to the start of study drug.
Women should not be lactating and, if of childbearing age, should have a negative pregnancy test (beta-human chorionic gonadotropin [b-HCG] test; serum or urine, minimum sensitivity  IU/L or equivalent units of b-HCG) within two week of registration in the study
Women of childbearing potential and men should practice effective methods of contraception. Women of childbearing potential should have a negative urine or serum pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin within  days prior to the start of PRI .
WOCBP must have a negative serum or urine pregnancy test [minimum sensitivity  UI/L or equivalent units of human chorionic gonadotrophin (HCG)] within  hours prior to the start of investigational product
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours before the start of ipilimumab
Women should not be lactating and, if of childbearing age, should have a negative pregnancy test (beta-human chorionic gonadotropin [b-HCG] test; serum or urine, minimum sensitivity  IU/L or equivalent units of b-HCG) within two week of registration in the study
Women must not be pregnant or breastfeeding; WOCBP must have a negative serum pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  days prior to registration
WOCBP must have a negative serum or urine pregnancy test (sensitivity ? IU human chorionic gonadotropin [hCG]/L) within  hours prior to the start of study drug administration
Women who are breast feeding or pregnant as evidenced by positive serum pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) done within  days of first dosing and urine test within  hours of first dosing
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours prior to surgery
Negative serum pregnancy test (minimum sensitivity  IU/L or equivalent units of human chorionic gonadotropin [HCG]) within  hours (hrs) prior to registration in women of child-bearing potential (WOCBP)
